Replies to post #243338 on Biotech Values

[DewDiligence]

EYES—>VANI, pursuant to previously announced reverse-merger.

https://www.businesswire.com/news/home/20220831005315/en

[DewDiligence]

VANI—(+313%)—reports preclinical data for Exenatide implant:

https://www.businesswire.com/news/home/20240228342864/en

Everyone is chasing the obesity market. Caveat emptor.

VANI (f/k/a Nano Precision Medicine) is the result of a 2022 reverse-merger (#msg-169535742).